Blockade of PD-1/PD-L1 axis is the novel immunotherapeutic modality with a striking clinical efficacy in the treatment of many solid tumors such as melanoma, renal cell carcinoma, non-small cell lung cancer, and certain malignancies with mismatch-repair deficiency [26–29]. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.